Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceraxa
- Development stage
- Unknown
- Lead developer
- PendreaBio
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Ceraxa is a fully synthetic, PEGylated nano-liposomal formulation of C6-ceramide developed by Keystone Nano, Inc. for the treatment of acute myeloid leukemia (AML). It functions by activating protein phosphatase 2A (PP2A), which leads to the dephosphorylation and inhibition of STAT3, thereby down-regulating pro-survival and pro-mitogenic signaling pathways in malignant cells. Additionally, Ceraxa has been shown to inhibit glycolysis, reduce tumor micro-vascularization, and counteract tumor-induced immunotolerance. It has been evaluated in a Phase 1 clinical trial for patients with relapsed or refractory AML to determine safety, tolerability, and pharmacokinetics.
- Brand names
- Ceraxa
- Other names
- Ceramide NanoLiposomeC6 Ceramide NanoLiposomeC-6 Ceramide NanoLiposomeC 6 Ceramide NanoLiposome
02
Targets
PP2A (Protein phosphatase 2A)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on Ceraxa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceraxa.